Jurema B. Schmidt

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Erratum to "Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas" [EJC 40 (2004) 1418].

Erratum to "Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas" [EJC 40 (2004) 1418].

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 22, 2026

Impact of a suspension drop onto a hot substrate: diminution of splash and prevention of film boiling.

Impact of a suspension drop onto a hot substrate: diminution of splash and prevention of film boiling.

Journal: Soft matter

Published: February 01, 2023

Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.

Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.

Journal: Journal of medicinal chemistry

Published: June 24, 2021

Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

Journal: ACS pharmacology & translational science

Published: January 28, 2021

A New FXR Ligand Chemotype with Agonist/Antagonist Switch.

A New FXR Ligand Chemotype with Agonist/Antagonist Switch.

Journal: ACS medicinal chemistry letters

Published: December 11, 2020

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice.

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice.

Journal: Communications chemistry

Published: May 04, 2020

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.

Journal: ChemMedChem

Published: October 15, 2019

A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Journal: Biochemical pharmacology

Published: February 14, 2019

Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.

Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.

Journal: Journal of medicinal chemistry

Published: February 01, 2019

Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL).

Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL).

Journal: Journal of medicinal chemistry

Published: November 09, 2018

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.

Journal: ChemMedChem

Published: August 14, 2018

Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.

Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.

Journal: Journal of medicinal chemistry

Published: June 08, 2018

Showing 1-12 of 28

Last Updated: 09/26/2026